-- 周三上午晚些时候，欧洲股市在美国交易，美国存托凭证（ADR）走高，标普欧洲精选ADR指数上涨1.98%，至1843.18点。 欧洲大陆方面，领涨的股票包括住宿预订公司trivago (TRVG)和荷兰国际集团(ING)，分别上涨14%和5%。紧随其后的是生物制药公司Cellectis (CLLS)和桑坦德银行(SAN)，分别上涨4.8%和4.2%。 欧洲大陆方面，领跌的股票包括互联网广告公司Criteo (CRTO)和石油炼制公司Equinor (EQNR)，分别下跌18%和8.4%。紧随其后的是半导体公司Sequans Communications (SQNS)和石油天然气公司Eni (E)，分别下跌5.8%和4.5%。 英国股市涨幅居前的股票包括生物制药公司Akari Therapeutics (AKTX)和保险公司Prudential (PUK)，分别上涨9.4%和6.2%。紧随其后的是矿业公司必和必拓集团(BHP Group)和巴克莱银行(BCS)，分别上涨5.3%和5.2%。 英国和爱尔兰股市跌幅居前的股票包括生物制药公司Mereo BioPharma Group (MREO)和NuCana (NCNA)，分别下跌5.1%和4%。其次是石油和天然气公司BP (BP)和壳牌(SHEL)，分别下跌3.7%和2.7%。
Related Articles
Australia
Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
$APTV$F
Research
Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
$CRTO
Australia
Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%
$OCUL